This setting lets you change the way you view articles. You can choose to have articles open in a dialog window, a new tab, or directly in the same window.
Open in Dialog
Open in New Tab
Open in same window
Open in New Tab
Open in same window

American Economic Review: Vol. 101 No. 3 (May 2011)
AER Volume. 101, Issue 3 |
Previous ArticleNext Article
Sign up for Email Alerts Follow us on Twitter
AER Forthcoming Articles
Full-text Article
Previous ArticleNext Article
Expand
Quick Tools:
Print Article Summary Email Link to this Article Export CitationSign up for Email Alerts Follow us on Twitter
Explore:
AER Forthcoming Articles
The Medium-Term Impact of Medicare Part D on Pharmaceutical Prices
Article Citation
Duggan, Mark G., and
Fiona Scott Morton. 2011. "The Medium-Term Impact of Medicare Part D on Pharmaceutical Prices."
American Economic Review,
101(3): 387-92.
DOI: 10.1257/aer.101.3.387
DOI: 10.1257/aer.101.3.387
Abstract
Medicare Part D began coverage of prescription drugs in 2006. Using data from the first year of the program we found that Part D reduced pharmaceutical prices for Medicare recipients, with these effects driven by enrollees previously without drug coverage. In this paper we extend our analysis through 2009, the fourth year of the program, to investigate whether plans continued to extract price concessions in return for favorable formulary placement, or if consumer inertia or other factors caused prices to bounce back after their initial decline. We find price declines persisted through at least the third year of the program.
Article Full-Text Access
Full-text Article
Authors
Duggan, Mark G. (U MD)
Scott Morton, Fiona (Yale U)
Scott Morton, Fiona (Yale U)
JEL Classifications
D12: Consumer Economics: Empirical Analysis
I18: Health: Government Policy; Regulation; Public Health
J14: Economics of the Elderly; Economics of the Handicapped; Non-labor Market Discrimination
I18: Health: Government Policy; Regulation; Public Health
J14: Economics of the Elderly; Economics of the Handicapped; Non-labor Market Discrimination

